In the BioHarmony Drug Report Database

"Preview" Icon

Isatuximab-irfc

Sarclisa (isatuximab) is an antibody pharmaceutical. Isatuximab was first approved as Sarclisa on 2020-03-02. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

 

Trade Name

 

Sarclisa
 

Common Name

 

isatuximab
 

ChEMBL ID

 

CHEMBL3545131
 

Indication

 

multiple myeloma
 

Drug Class

 

Monoclonal antibodies: chimeric, tumors as target

Image (chem structure or protein)

Isatuximab-irfc structure rendering